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Purpose.TheincidenceofClostridiumdiﬃcile-associateddiarrhea(CDAD)hassteadilyincreasedoverthepastdecade.Amultitude
of factors for this rise in incidence of CDAD have been postulated, including the increased use of gastric acid suppression therapy
(GAST). Despite the presence of practice guidelines for use of GAST, studies have demonstrated widespread inappropriate use of
GAST in hospitalized patients. We performed a retrospective analysis of inpatients with CDAD, with special emphasis placed on
determiningtheappropriatenessofGAST.Methods.Aretrospectiveanalysiswasconductedatamultidisciplinaryteachinghospital
on inpatients with CDAD over a 10-year period. We assessed the use of GAST in the cases of CDAD. Data collection focused on
the appropriate administration of GAST as deﬁned by standard practice guidelines. Results. An inappropriate indication for GAST
was not apparent in a majority (69.4%) of patients with CDAD. The inappropriate use of GAST was more prevalent in medical
(86.1%) than on surgical services (13.9%) (P<0.001). There were more cases (67.6%) of inappropriate use of GAST in noncritical
care than in critical care areas (37.4%) (P<0.001). Conclusion. Our study found that an inappropriate use of inpatient GAST in
patients with CDAD was nearly 70 percent. Reduction of inappropriate use of GAST may be an additional approach to reduce the
risk of CDAD and signiﬁcantly decrease patient morbidity and healthcare costs.
1.Introduction
Clostridium diﬃcile (C. diﬃcile), a Gram-positive, sporu-
lating, anaerobic bacterium, is the most common cause of
nosocomial diarrhea in the United States [1]. The reported
cases of C. diﬃcile-associated diarrhea (CDAD) have steadily
increased over the past decade, with a reported incidence
of 0.1–2% in all hospitalized patients [1]. A multitude of
risk factors for CDAD have been identiﬁed, with the most
commonlycitedfactorbeingtheuseofantibiotictherapy[1–
3]. Review of literature suggests that the use of gastric acid
suppression therapy (GAST) is associated with increasing
incidence of CDAD [1–3]. A suggested mechanism for this
association is believed to be the increase in gastric pH
secondary to GAST, allowing for the survival of the C.
diﬃcile bacteria and spores [1]. Gastric acid suppression is
commonly achieved with the use of proton pump inhibitors
(PPIs) and histamine-2 receptor antagonists (H2As). There
has been increased use of GAST, especially PPIs in the last
decade, correlating with the increased incidence of CDAD
[4, 5]. Although an appropriate indication for the use of
GAST is often present, inappropriate use of such therapy is
frequentlyobservedinaninpatientsetting,possiblyresulting
in an increased incidence of nosocomial CDAD [1, 4, 6].
We performed a retrospective analysis of hospitalized
patients with CDAD, with a focus on determining the
appropriateness of GAST.
2. Methods
A retrospective analysis was conducted at Nassau University
Medical Center; a 631-bed multidisciplinary teaching hos-
pital, a part of the North Shore-Long Island Jewish Health
System located in East Meadow, New York.2 ISRN Gastroenterology
Datawasobtainedforallinpatients ≥18yearsofagefrom
January, 1 2001 to December 31, 2010 who developed CDAD
during hospitalization using inpatient medical records after
obtaining approval from the hospital’s Institutional Review
Board (IRB).
Cases were identiﬁed using discharge diagnosis of CDAD
based on the relevant diagnostic (ICD-9) codes and con-
ﬁrmed by the presence of positive stool C. diﬃcile toxins
A and B along with associated new onset diarrhea ≥3d a y s
after admission. Patients with prior history of CDAD prior
to admission were excluded from the study.
We assessed the use of GAST in the cases of CDAD,
as this appears to be an established risk factor for CDAD.
GAST was deﬁned as the use of PPIs or H2As after admission
to the inpatient service. All patients receiving GAST prior
to the ﬁrst day of admission were excluded from the
study. Data collection focused on chart references indicating
the reason GAST was administered, via documentation
under the “Assessment and Plan” section of the admission
progress note. Appropriate uses of GAST for stress ulcer
prophylaxis were deﬁned by the American Society of Health-
System Pharmacists (AHSP) practice guidelines (Table 1).
Appropriate administration of GAST for an established
gastrointestinal diagnosis was deﬁned by the Food and Drug
Administration’s approval guidelines for PPI use (Table 2).
If the indication for the use of GAST did not meet the
guidelines set by the FDA or AHSP; the use of GAST
was deemed inappropriate. Cases of CDAD wherein the
indication for GAST was not documented were excluded
from the study.
3. Statistics
Statistical analysis was performed using the SPSS (version
19). Diﬀerences between the patient groups were tested for
statistical signiﬁcance using chi-square analysis. A P value of
<0.05 was considered statistically signiﬁcant.
4. Results
A total of 770 patients were identiﬁed to have a discharge
diagnosis of CDAD based on relevant International Classiﬁ-
cation of Diseases (ICD-9) codes. 515 patients (66.9%) were
foundtobepositivefortheC.diﬃciletoxinA/B.Ofthose515
patients, 326 (63.3%) were noted to have CDAD for the ﬁrst
time.207(63.5%)patientsthatwerenotedtohaveCDADfor
the ﬁrst time, were on GAST at home, and of the remaining
119 (36.5%) patients, 108 (90.8%) were started on inpatient
GAST and further analyzed in our study (Figure 1).
ThemeanageofpatientswithCDADwas70years(range
35–97 years). 46 (42.6%) cases were female and 62 (57.4%)
were male. The earliest and the latest diagnosis of CDAD
after starting inpatient GAST was 4 days and 154 days,
respectively; with the average mean duration being 32.4 days
(P<0.001).19.4%ofpatientswhodevelopedCDADdidnot
receive any antibiotic therapy.
The length of hospital stay after development of CDAD
rangedfrom4to177days,thoughthismeasuredidnotreach
Table 1: ASHP therapeutic guidelines on stress ulcer prophylaxis
[7].
Intensive care unit (ICU) patient plus one of the following:
(1) Coagulopathy (i.e., platelet count of <50,000mm3, inter-
national normalized ratio (INR) >1.5, or an activated partial
thromboplastin time (aPTT) >2 times control)
(2) Mechanical ventilation for >48 hours
(3) History of gastrointestinal ulceration or bleeding within one
year of admission
(4) Glasgow coma score of ≤10
(5) Thermal injury to >35% of body surface area
(6) Partial hepatectomy
(7) Multiple trauma (injury severity score of ≥16)
(8) Transplantation perioperatively in the ICU
(9) Spinal cord injury
(10) Hepatic failure
(11) Two or more of the following risk factors: sepsis, ICU stay
of greater than one week, occult bleeding lasting at least six days,
and high-dose corticosteroids (>250mg/day of hydrocortisone)
Table 2: FDA approved indications for use of proton pump
inhibitors [8–14].
(1) Healing of erosive esophagitis
(2) Maintenance of healing of erosive esophagitis
(3) Symptomatic gastroesophageal reﬂux disease
(4) Helicobacter pylori eradication in combination with anti-
biotics
(5) Short-term treatment of active gastric ulcer
(6) Short-term treatment of active duodenal ulcer
(7) Maintenance of healed duodenal ulcer
(8) Healing of NSAID-Associated gastric ulcer
(9) Risk reduction of NSAID-associated gastric Ulcer
(10) Risk reduction of upper gastrointestinal bleeding in criti-
cally Ill patients
(11)PathologicalhypersecretoryconditionsincludingZollinger-
Ellison syndrome
Abbreviations: FDA, Food and Drug Administration; NSAID, non-steroidal
anti-inﬂammatory drugs.
statistical signiﬁcance, but could have signiﬁcantly increased
the health care costs.
In our study, 81 (75%) patients received inpatient PPI
therapy,andtheremaining27(25%)receivedH2Asasaform
of GAST. Of patients receiving PPI therapy, 76.4% received a
total daily dose of 40mg and 23.6% received a daily dose of
80mg.ThedoseofH2Asusedinallofourpatientswas40mg
daily. Since our sample size was small, and the majority of
patients received a similar dose; a dose correlation with the
development of CDAD was beyond the scope of this study.
An appropriate indication for use of inpatient GAST was
seen only in 33 (30.6%) cases, while an inappropriate use
(Table 3) was seen in 75 (69.4%) cases. The inappropriate
use of GAST was more prevalent in medical (86.7%) than
surgical (13.3%) services (P<0.001). Inappropriate use ofISRN Gastroenterology 3
ICD diagnosis of
CDAD
770
CDAD (toxin
negative)
Prior CDAD First episode of
CDAD
hospital
PPI H2A
GAST at home No GAST at home
GAST started in No GAST in hospital
255 (33.1%) 515 (66.9%)
189 (24.5%) 326 (42.3%)
207 (26.9%) 119 (15.4%)
108 (14%)
11 (1.4%)
81 (10.5%) 27 (3.5%)
CDAD (toxin positive)
Figure 1: Chart review algorithm for CDAD case selection. ICD: International Classiﬁcation of Diseases; CDAD: Clostridium diﬃcile-
associated diarrhea; GAST: gastric acid suppression therapy; PPI: proton pump inhibitor; H2A: histamine-2 receptor antagonist. Note:
number in parenthesis indicates percentage of cases.
GAST was greater in noncritical care (67.6%) than critical
care units (37.4%) (P<0.001).
5. Discussion
AnassociationbetweenGASTandCDADhasbeenproposed
in prior studies [1–3, 6, 15–18]. Our study was designed
to assess the appropriateness of GAST in patients who
developed CDAD.
Clostridium diﬃcile infection (CDI) is the most common
cause of infectious diarrhea in a nosocomial setting [15]. In
United States, approximately 500,000 cases of CDI have been
estimated to be present in hospitals and nursing homes [19,
20]. The incidence of CDI in the United States has increased
three times over the last decade [20].
A potential mechanism for an association between GAST
and CDAD includes an increased pH in the stomach,
leading to the growth of pathogenic bacterial ﬂora in the
gastrointestinal tract.C .d i ﬃcile spores are acid-resistant
but vegetative forms are susceptible to gastric acidity [3, 5,
16, 21]. It has been shown in a hamster model that most
of the ingested spores are transformed into the vegetative
state within 60 minutes of ingestion, likely in the stomach
[21]. It is therefore possible that an increase in gastric pH
secondary to GAST may result in germination of sporulated
to vegetative forms of C. diﬃcile in the stomach, leading4 ISRN Gastroenterology
Table 3: Documented inappropriate indications for gastric acid
suppression therapy [7–14].
Inappropriate indication Percent of patients
Indeterminate chest pain 30.6%
Nonspeciﬁc abdominal pain 22.6%
Coprescribed with aspirin 14.6%
Coprescribed with low dose steroids 12.0%
Coprescribed with warfarin 10.6%
Coprescribed with antibiotics 5.6%
NPO (nulla per os; nothing by mouth) 2%
Nausea 2%
to increased colonization with C. diﬃcile and subsequent
CDAD [21].
The use of GAST for the treatment of gastrointestinal
acid-secretory disorders such as gastroesophageal reﬂux
disease (GERD) and peptic ulcer disease (PUD); along with
stress ulcer prophylaxis has increased [20]. PPIs have now
replaced H2As as the leading GAST due to their more potent
acid suppressing properties [20]. Pham et al. found a 140%
increase in the use of GAST in patients after admission to
the hospital in recent years. The US Pharmaceutical Market
Report suggests that over 12.4 billion dollars is spent on the
u s eo fP P I sa n n u a l l y[ 20, 22].
The practice guidelines available for the use of GAST
for stress ulcer prophylaxis were published by the American
Society of Health-System Pharmacists (Table 1)[ 7]. The
appropriate indications of PPI therapy in the treatment
of gastrointestinal acid-secretory disorders have been high-
lighted by the US Food and Drug Administration (FDA)
(Table 2) and are also evident in recent clinical studies [8–
14].
Despite the presence of practice guidelines for the use of
GAST, multiple studies have demonstrated inappropriate use
of GAST in an inpatient setting. Zink et al, and Nardino et
al. found an inappropriate indication for GAST prescription
in 60% and 72% of all inpatients respectively [23, 24].
The ﬁnancial impact resulting from the overuse of GAST
was illustrated in a study by Heidelbaugh et al. In this
study of nearly 1880 inpatients, 22% were found to have
an inappropriate indication for GAST, and of those, 54%
were discharged home with GAST. The estimated cost of
inappropriate GAST from this cohort was nearly $111,000
p e ry e a r[ 2].
Our study highlights the fact that the inappropriate use
of GAST is common, especially in noncritical care patients,
and on medical services.
Although clinicians often view GAST as harmless, its use
isnotwithoutmedicalrisksandstrongﬁnancialimplications
[2, 25–27].
Interventions aimed at improving physician education
regarding the appropriate use of GAST may be an additional
approach to reduce the risk of CDAD and will signiﬁcantly
decrease healthcare costs.
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